Resource Hub
VIRTUAL TOUR
CONTACT US
Our Company
Investors
Services
Our Responsibility
Careers
Our Company
Investors
Services
Our Responsibility
Careers
© 2024 Aragen Bioscience. All rights reserved
Back
About Us
Our Journey
Leadership
Scientific and BD Team
Aragen Advantage
Investors
Global Locations
Media & Events
Recognitions
Disclosures under Regulation 62 of the LODR
Corporate Governance
Small Molecules
Large Molecules (Biologics)
Discovery
Aragen Integrated Drug Discovery (AIDD)
Integrated Drug Discovery
Chemistry
Biology
Safety Assessment
Development & Manufacturing
Drug Substance - new
Drug Substance
Drug Product
Analytical Development
Performance Chemicals
Custom Chemical Synthesis
Commercial Manufacturing
Discovery
Integrated Discovery
Molecular Biology
Antibody Discovery
Protein Sciences
Cell Line Development
Biology
Development & Manufacturing
Process Research & Development
Bioproduction
Developability & Analytics
GMP Manufacturing
EHS & Sustainability
Strategic Supply Chain Management
Quality
IP Protection & Data Security
Employee Welfare
Corporate Social Responsibility
Corporate Governance
Working at Aragen
Career Opportunities
Meet Our People
Caution Notice
Close Search
Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
GET IN TOUCH
Back to Resources
Articles
Filter by Science
All
All
Analytical
Biologics
Biology
Chemistry
Development
Ecotoxicology
Formulations BU
Intox
Manufacturing
NBEs Intox
PCET
SAS/Toxicology
Solutions for Mitigating Challenges in Recombinant Protein Production
Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics
Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels
Clinically relevant preclinical model of CFA-Induced inflammatory pain
A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells
Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data
Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences
Aragen’s quantitative proteomics sampling capabilities: Accurate and Reproducible Workflows
Experimental pain models at Aragen Life Sciences – Spinal Nerve Ligation (SNL) Model of Neuropathic Pain
Pharmacokinetics (PK)/ Pharmacodynamics (PD) and Mechanistics solutions in Ellegaard Göttingen Minipigs
Comprehensive Characterization of Biologics
Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.
Automation to miniaturize
In vitro
assays to achieve superior and cost-efficient results
Targeted Protein Degradation
Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice
Cell line development capabilities
Cell line development comprehensive solutions
Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics
Industry Leading Hybridoma Technique for Accelerated Antibody Discovery
Covalent Drugs – Advantages, Challenges, And Opportunities
Mitigating CMC issues through Aragen’s holistic approach to developability assessment
Aragen’s Preclinical Oncology Capabilities – Tumor Imaging
Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models
Aragen’s Oncology solutions: Accelerate your cancer therapeutics development
RSV Challenge Model for anti-RSV therapy
Cell Line Development at Aragen: Research cell banks in 5 months
Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models
DSS-induced IBD Mouse Model for preclinical drug screening
Cell Line Development at Aragen; Accelerating speed to IND
Learn more about our end-to-end capabilities
×
Contact An Expert Today!
Contact Us
+
+